Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: A phase II study

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 5, 2004, Pages 387-392

  Padrik, Peeter ^a   Leppik, Krista ^a   Arak, Andrus ^a  

^a TARTU UNIVERSITY CLINICS   (Estonia)

Author keywords

Capecitabine; Chemotherapy; Immunotherapy; Interferon alfa; Renal cell carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA2A INTERFERON; BILIRUBIN; CAPECITABINE; CREATININE; RECOMBINANT ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; MALE; MEDICAL ASSESSMENT; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; THROMBOCYTOPENIA; VAGINITIS; WEIGHT REDUCTION; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 16644368159     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2003.11.014     Document Type: Article

References (34)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden Globocan 2000. Int J Cancer. 94:2001;153-156
2. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin. 49:1999;33-64
3. Savage P.D. Renal cell carcinoma. Curr Opin Oncol. 8:1996;247-251
4. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma 1983-1993. Semin Oncol. 22:1995;42-60
5. Hartmann J.T., Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res. 19:1999;1541-1543
6. Motzer R.J. Renal cell carcinoma progress against an elusive tumor. Semin Oncol. 27:2000;113-114
7. Amato R.J. Chemotherapy for renal cell carcinoma. Semin Oncol. 27:2000;177-186
8. Bukowski R.M. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 19:2001;148-154
9. Heinzer H., Huland E., Huland H. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol. 19:2001;111-119
10. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 17:1999;2859-2867
11. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma early results of a randomised controlled trial. Lancet. 353:1999;14-17
12. Coppin C., Porzsolt F., Kumpf J., Coldman A., Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2000;CD001425
13. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58:1998;685-690
14. Miwa M., Ura M., Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1998;1274-1281
15. Mackean M., Planting A., Twelves C., et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 16:1998;2977-2985
16. Schuller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 45:2000;291-297
17. Twelves C. Vision of the future capecitabine. Oncologist 6 Suppl. 4:2001;35-39
18. Oevermann K., Buer J., Hoffmann R., et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer. 83:2000;583-587
19. Wenzel C., Locker G.J., Schmidinger M., et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis. 39:2002;48-54
20. Chang D.Z., Olencki T., Budd G.T., et al. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer toxicity and pharmacokinetics. Cancer Chemother Pharmacol. 48:2001;493-498
21. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:2000;205-216
22. Gehan E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 13:1961;346-353
23. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
24. Fossa S.D. Interferon in metastatic renal cell carcinoma. Semin Oncol. 27:2000;187-193
25. Fossa S.D., Martinelli G., Otto U., et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma results of a European multi-center phase III study. Ann Oncol. 3:1992;301-305
26. De Mulder P.H., Oosterhof G., Bouffioux C., van Oosterom A.T., Vermeylen K., Sylvester R. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer. 71:1995;371-375
27. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 338:1998;1272-1278
28. Motzer R.J., Murphy B.A., Bacik J., et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 18:2000;2972-2980
29. Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma a randomised trial. Lancet. 358:2001;966-970
30. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 345:2001;1655-1659
31. Bukowski R.M. Cytokine combinations therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol. 27:2000;204-212
32. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer results of a randomized phase III study. J Clin Oncol. 19:2001;2282-2292
33. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer results of a large phase III study. J Clin Oncol. 19:2001;4097-4106
34. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer phase III trial results. J Clin Oncol. 20:2002;2812-2823